CTR20262832 TARLATAMAB-DLLE Extensive stage Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20262832 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 3 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20262832 is a hot trial to watch
Extensive stage Small Cell Lung Cancer is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20262832 is notable because it evaluates TARLATAMAB-DLLE in a Phase 3 design sponsored by Amgen, Inc.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20262832 |
| Official title | 比较Tarlatamab（SC vs. IV）治疗含铂一线化疗后广泛期小细胞肺癌的3 期试验（DeLLphi-315） |
| Phase / status | Phase 3 / 进行中 （尚未招募） |
| Intervention | TARLATAMAB-DLLE |
| Sponsor | Amgen, Inc. |
| Geography | Brazil, United States, Romania, Poland, Switzerland, Taiwan Province, France, Italy, South Korea, Netherlands, Canada, Japan, Germany, Turkey, Greece, Portugal, China, Spain, Australia, United Kingdom, Hungary, Belgium |
| Enrollment | [object Object],[object Object] |
| Primary endpoint | |
| Endpoint time frame | 第2周期第1天至第15天 |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 3 study of TARLATAMAB-DLLE in Extensive stage Small Cell Lung Cancer.
Allocation is 随机化, masking is 开放, and the intervention model is 平行分组. Planned enrollment of [object Object],[object Object] participants across Brazil, United States, Romania, Poland, Switzerland, Taiwan Province, France, Italy, South Korea, Netherlands, Canada, Japan, Germany, Turkey, Greece, Portugal, China, Spain, Australia, United Kingdom, Hungary, Belgium shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (第2周期第1天至第15天) — Tarlatamab药代动力学（PK）参数：曲线下面积（AUCC2D1-D15）、给药前浓度（Ctrough）
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: TARLATAMAB-DLLE is indexed as Bispecific T-cell Engager (BiTE), with target CD3 x DLL3, mechanism CD3 stimulants, DLL3 inhibitors, and global highest development status Approved.
Company & Deal Intelligence MCP profile: Amgen, Inc. is resolved to a normalized organization record in VENTURA COUNTY, United States. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20262832 provides a focused lens on Extensive stage Small Cell Lung Cancer development. Its value will be determined by whether TARLATAMAB-DLLE can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
